Thoracic Oncology and Advanced Solid Tumours
Research activity includes non-small cell lung cancer, small-cell lung cancer, and other poorly differentiated neuroendocrine carcinomas, with additional interest in pancreatic ductal adenocarcinoma, oligometastatic disease, and biomarker-defined tumour subsets.
- NSCLC
- SCLC and neuroendocrine carcinomas
- Pancreatic cancer
- Oligometastatic solid tumours
Work in this area also extends to metastatic renal cell carcinoma and KRAS G12C-mutated lung cancer, reflecting a strong focus on targeted and immunologic treatment strategies.
Breast Cancer and Hormone-Receptor–Driven Disease
The sponsor funds studies across early-stage breast cancer, triple-negative breast cancer, HER2-positive and HER2-low disease, as well as advanced hormone-receptor positive breast cancer and treatment-related symptom control.
- Triple-negative breast cancer
- HER2-positive and HER2-low breast cancer
- Hormone-receptor positive advanced breast cancer
- Adjuvant endocrine therapy-related pain
Its portfolio also includes window-of-opportunity and neoadjuvant investigations in breast cancer, with attention to immune response and molecularly selected subgroups.
Gastrointestinal, Hepatobiliary, and Pelvic Malignancies
Clinical research spans rectal adenocarcinoma, colorectal cancer, hepatocellular carcinoma, cervical cancer, and HPV-related squamous intraepithelial lesions, with a recurring interest in organ preservation and local control.
- Rectal cancer
- Hepatocellular carcinoma
- Cervical and anal HPV-related disease
- Metastatic colorectal cancer
Additional activity covers mucosal melanoma and head and neck squamous cell carcinoma, including postoperative and radiotherapy-linked treatment settings.
Haematological Malignancies and Pediatric Oncology
Funding supports studies in acute myeloid leukemia, relapsed/refractory ALK-positive anaplastic large cell lymphoma, high-risk neuroblastoma, diffuse intrinsic pontine glioma, and other pediatric and adolescent cancers.
- Acute myeloid leukemia
- ALK-positive anaplastic large cell lymphoma
- High-risk neuroblastoma
- Diffuse midline glioma
The portfolio also includes germ-cell tumours and molecularly enriched paediatric solid tumours, with emphasis on refractory and high-risk disease.
Rare Tumours, Genomic Subtypes, and Immunotherapy
Research extends to sarcoma, mucosal melanoma, renal carcinoma, endometrial cancer, and other molecularly selected solid tumours defined by DNA repair deficiency, chromatin remodelling alterations, or tertiary lymphoid structures.
- Soft tissue sarcoma
- Endometrial cancer
- DNA repair-deficient tumours
- Immune checkpoint–based therapy
Across these programmes, the sponsor is active in biomarker-driven oncology, radiotherapy combinations, and personalised treatment for uncommon and difficult-to-treat malignancies.
